<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4009">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584541</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200598</org_study_id>
    <nct_id>NCT04584541</nct_id>
  </id_info>
  <brief_title>SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism</brief_title>
  <acronym>COVIRIC</acronym>
  <official_title>Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether immunosuppressive therapies used by patients&#xD;
      with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral&#xD;
      and cellular responses during viral infection with SarSCoV2, compared to members of their&#xD;
      family cluster infected with the same viral strain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) and spondyloarthritis (SPA) are the two most common chronic&#xD;
      inflammatory rheumatic diseases, with a prevalence of 0.5-1% for RA and about 0.35% for SPA.&#xD;
      Many studies have described an increased risk of serious infectious diseases directly&#xD;
      associated with increased morbidity and mortality among those patients. This increased risk&#xD;
      (frequency and severity) results from the disease itself, especially if the rheumatism is not&#xD;
      controlled with high disease activity, but also due to the immunosuppressive treatments used&#xD;
      to treat these patients. The risk of infection is measured by the Incidence Rate (IR)&#xD;
      corresponding to the number of events (infections) per 100 patients/years of follow-up. This&#xD;
      risk is accepted as comparable between patients with SpA or RA and ranges from 22 to 34/100&#xD;
      patient-years, depending on the studies, for patients on biologics. The risk of infection is&#xD;
      higher for patients on biotherapy than for patients on Disease Modifying Anti-Rheumatic Drugs&#xD;
      (DMARDs - mainly Methotrexate) and the combination of corticosteroid therapy with the&#xD;
      biotherapies further increases this risk of infection. Lung and upper respiratory tract&#xD;
      infections are the most common infections observed under biotherapy. The risk of infection&#xD;
      may be different depending on the biotherapy considered. Moreover, the vaccine response is&#xD;
      also highly variable depending on the biotherapy, treatments with Rituximab, methotrexate and&#xD;
      abatacept being those interfering the most with the quality of the vaccine response. The&#xD;
      working hypothesis is therefore that certain immunosuppressive treatments used in these&#xD;
      inflammatory rheumatic conditions may interfere with the humoral and/or cellular&#xD;
      anti-SarS-Cov-2 immune response.&#xD;
&#xD;
      Since December 2019, the first SARS-Cov-2 (Severe acute respiratory coronavirus 2 syndrome)&#xD;
      infections have been described in Wuhan province in China. In April 2020, 1,824,950 people&#xD;
      were officially infected in 193 countries worldwide with 112,510 deaths reported (Agence&#xD;
      France Presse and World Health Organization; 13 April 2020). To date, the investigators have&#xD;
      a limited amount of data concerning the seroconversion of infected subjects, the protective&#xD;
      or non-protective nature of the specific antibodies generated, and the duration of&#xD;
      protection. No data have been generated on the specific B and T responses of SarS-Cov-2. In&#xD;
      addition, the few available data in the literature on SarS-Cov-2 only concern the general&#xD;
      population, not exposed to immunosuppressive treatments.&#xD;
&#xD;
      However, major questions are currently unanswered for patients on immunosuppressive&#xD;
      treatments: Are they excreting the virus for longer periods of time? How long can this viral&#xD;
      excretion be measured in the upper airways and in the stool? Do they develop a humoral and&#xD;
      cellular immune response similar to the general population? Accurate knowledge of the&#xD;
      dynamics of the virus and the immune response induced will be essential for the development&#xD;
      of strategies for antiviral treatment, vaccination protocols and for the epidemiological&#xD;
      control of Covid-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs</measure>
    <time_frame>up to Day 30</time_frame>
    <description>Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs</measure>
    <time_frame>between Day 30 and Day 90</time_frame>
    <description>Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood</measure>
    <time_frame>up to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood</measure>
    <time_frame>between Day 30 and Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Isolation and characterization of B and T lymphocytes in blood</measure>
    <time_frame>up to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Isolation and characterization of B and T lymphocytes in blood</measure>
    <time_frame>between Day 30 and Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Isolation and characterization of B and T lymphocytes in blood</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Isolation and characterization of B and T lymphocytes in blood</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Isolation and characterization of B and T lymphocytes in blood</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Spondyloarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>case</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Index cases (RA and SpA patients under immunosuppressive treatments)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Members of index cases family cluster infected with the same viral strain</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood tests</intervention_name>
    <description>Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)</description>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>controls</arm_group_label>
    <other_name>Immune response assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nasopharyngeal swabs</intervention_name>
    <description>SarS-Cov-2 viral load assessment</description>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stools</intervention_name>
    <description>SarS-Cov-2 viral load assessment</description>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        cases&#xD;
&#xD;
          -  Patient with spondyloarthritis fulfilling the ASAS criteria&#xD;
&#xD;
          -  Patients with rheumatoid arthritis fulfilling the ACR/EULAR criteria and&#xD;
&#xD;
          -  Immunosuppressive therapy: Methotrexate, leflunomide, anti-TNF, Anti-IL6R, abatacept,&#xD;
             rituximab, Jak inhibitors (tofacitinib or baricitinib) And&#xD;
&#xD;
          -  infected with the SarS-Cov-2 (positive PCR and/or serology and/or CT-scan)&#xD;
&#xD;
        Controls:&#xD;
&#xD;
          -  Family cluster member confined to the same location as the index subject&#xD;
&#xD;
          -  Infected with the SarS-Cov-2 (positive PCR and/or serology and/or CT-scan)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        cases and controls&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Breastfeeding woman&#xD;
&#xD;
          -  Immunosuppressed subject for members of the familiar cluster of the index subject&#xD;
&#xD;
          -  Patient with no social security&#xD;
&#xD;
          -  Patients whose freedom is limited by the judicial or administrative authority&#xD;
&#xD;
          -  Patients under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Miceli-Richard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Miceli-Richard, MD, PhD</last_name>
    <phone>1 58 41 26 06</phone>
    <phone_ext>+33</phone_ext>
    <email>corinne.miceli@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adèle bellino</last_name>
    <phone>158411195</phone>
    <phone_ext>+33</phone_ext>
    <email>adele.bellino@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Miceli-Richard, MD, PhD</last_name>
      <phone>1 40 61 38 22</phone>
      <phone_ext>+33</phone_ext>
      <email>corinne.miceli@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spondyloarthritis</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Immunosuppressive treatments</keyword>
  <keyword>COVID19</keyword>
  <keyword>Sars-Cov-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

